vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 phase 3 trial in type 1 diabetes.
Portfolio Pulse from Benzinga Newsdesk
vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program, including the ongoing CATT1 phase 3 trial in type 1 diabetes.
July 26, 2024 | 8:37 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
vTv Therapeutics shares are trading lower due to the FDA placing a clinical hold on their cadisegliatin clinical program, which includes the ongoing CATT1 phase 3 trial in type 1 diabetes.
The FDA's clinical hold on the cadisegliatin program is a significant regulatory setback for vTv Therapeutics, directly impacting their ongoing CATT1 phase 3 trial. This news is likely to negatively affect investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100